End-of-day quote
Korea S.E.
23:00:00 27/06/2024 BST
|
5-day change
|
1st Jan Change
|
2,705
KRW
|
-2.35%
|
|
-1.99%
|
-28.44%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
586,015
|
233,826
|
175,143
|
77,366
|
Enterprise Value (EV)
1 |
557,357
|
220,353
|
171,942
|
68,849
|
P/E ratio
|
-45.3
x
|
-8.61
x
|
-6.35
x
|
-2.58
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,831
x
|
532
x
|
442
x
|
111
x
|
EV / Revenue
|
1,742
x
|
502
x
|
434
x
|
99
x
|
EV / EBITDA
|
-37.5
x
|
-20
x
|
-14.9
x
|
-5.66
x
|
EV / FCF
|
-32.5
x
|
-22.9
x
|
-22.4
x
|
-7.91
x
|
FCF Yield
|
-3.08%
|
-4.37%
|
-4.46%
|
-12.6%
|
Price to Book
|
9.29
x
|
5.24
x
|
7.15
x
|
3.78
x
|
Nbr of stocks (in thousands)
|
14,250
|
14,426
|
14,545
|
20,467
|
Reference price
2 |
41,125
|
16,208
|
12,042
|
3,780
|
Announcement Date
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
28.76
|
168.5
|
320
|
439.3
|
396
|
695.7
|
EBITDA
1 |
-8,247
|
-11,039
|
-14,858
|
-11,020
|
-11,538
|
-12,158
|
EBIT
1 |
-8,569
|
-12,202
|
-16,089
|
-12,155
|
-12,579
|
-12,998
|
Operating Margin
|
-29,792.04%
|
-7,241.7%
|
-5,027.71%
|
-2,767.18%
|
-3,176.64%
|
-1,868.29%
|
Earnings before Tax (EBT)
1 |
-40,095
|
-42,554
|
-9,633
|
-22,519
|
-22,930
|
-23,961
|
Net income
1 |
-40,095
|
-42,554
|
-9,633
|
-22,519
|
-22,930
|
-23,961
|
Net margin
|
-139,404.45%
|
-25,254.54%
|
-3,010.19%
|
-5,126.47%
|
-5,790.66%
|
-3,444.23%
|
EPS
2 |
-22,149
|
-8,083
|
-908.2
|
-1,882
|
-1,897
|
-1,464
|
Free Cash Flow
1 |
18,468
|
-31,378
|
-17,164
|
-9,620
|
-7,677
|
-8,706
|
FCF margin
|
64,210.31%
|
-18,621.91%
|
-5,363.72%
|
-2,190.04%
|
-1,938.6%
|
-1,251.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
15,282
|
16,880
|
28,658
|
13,473
|
3,201
|
8,518
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
18,468
|
-31,378
|
-17,164
|
-9,620
|
-7,677
|
-8,706
|
ROE (net income / shareholders' equity)
|
236%
|
869%
|
-22.3%
|
-41.8%
|
-66.3%
|
-107%
|
ROA (Net income/ Total Assets)
|
-21.3%
|
-18%
|
-17.1%
|
-11.7%
|
-18.1%
|
-27.8%
|
Assets
1 |
188,279
|
236,845
|
56,198
|
193,171
|
126,968
|
86,164
|
Book Value Per Share
2 |
-24,637
|
1,113
|
4,427
|
3,092
|
1,685
|
1,001
|
Cash Flow per Share
2 |
6,302
|
293.0
|
5.440
|
200.0
|
476.0
|
220.0
|
Capex
1 |
968
|
9,273
|
1,480
|
676
|
505
|
236
|
Capex / Sales
|
3,366.11%
|
5,503.52%
|
462.36%
|
153.89%
|
127.49%
|
33.86%
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
|
1st Jan change
|
Capi.
|
---|
| -28.44% | 40.18M | | +15.20% | 121B | | +19.67% | 113B | | +17.26% | 26.02B | | -23.86% | 19.39B | | -18.79% | 15.91B | | -20.90% | 15.09B | | -46.14% | 15.06B | | +63.85% | 14.93B | | +4.49% | 13.85B |
Bio Therapeutic Drugs
|